Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats.

Psychopharmacology·2023
Same author

Therapeutic Differences in 24-h Ambulatory Blood Pressures in Patients Switched Between Bioequivalent Nifedipine Osmotic Systems With Differing Delivery Technologies.

Clinical and translational science·2017
Same author

Drug interactions and the statins.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·1999
Same author

A cardiovascular risk factor reduction clinic.

The Canadian journal of cardiology·1999
Same author

Changes in the position and angulation of incisura during contractions of the isolated cat stomach.

Neurogastroenterology and motility·1998
Same author

Contractions move contents by changing the configuration of the isolated cat stomach.

The American journal of physiology·1998
Same journal

Impact of virtual case conferences between primary care clinicians and an interdisciplinary chronic pain clinic.

Canadian family physician Medecin de famille canadien·2026
Same journal

Canadian family physician Medecin de famille canadien·2026
Same journal

Predictors of high-performing family medicine clinics: Prospective cohort study in Alberta.

Canadian family physician Medecin de famille canadien·2026
Same journal

Acetylsalicylic acid use for artial fibrillation and bleeding risk.

Canadian family physician Medecin de famille canadien·2026
Same journal

Clinical practice guidelines: Important tools to teach the art of medicine.

Canadian family physician Medecin de famille canadien·2026
Same journal

Paratonia in advanced dementia: Challenges and evidence-based interventions.

Canadian family physician Medecin de famille canadien·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

Arrhythmias: antiarrhythmic agents.

R J Herman

    Canadian Family Physician Medecin De Famille Canadien
    |January 26, 2011
    PubMed
    Summary
    This summary is machine-generated.

    Sudden cardiac death from ventricular arrhythmias is a major concern. New detection methods and drugs are expanding treatment options, making this topic relevant for general physicians.

    More Related Videos

    Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
    07:42

    Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

    Published on: October 18, 2018

    Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
    08:56

    Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

    Published on: September 24, 2021

    Related Experiment Videos

    Last Updated: Jun 5, 2026

    Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
    08:28

    Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

    Published on: April 5, 2011

    Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
    07:42

    Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

    Published on: October 18, 2018

    Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
    08:56

    Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

    Published on: September 24, 2021

    Area of Science:

    • Cardiology
    • Public Health

    Background:

    • Ventricular tachycardia/fibrillation leading to sudden cardiac death is a significant public health issue.
    • The complexity and limited therapeutic options have historically confined this field to specialists.
    • Advances in risk identification, monitoring, and antiarrhythmic drugs are increasing interest.

    Purpose of the Study:

    • To provide an update on arrhythmias and sudden cardiac death.
    • To highlight the broadening interest in this field due to recent advancements.
    • To emphasize the importance of this topic for family physicians and generalists.

    Main Methods:

    • Review of recent studies identifying individuals at risk for dysrhythmia.
    • Evaluation of improved detection and monitoring methods.
    • Assessment of new potent antiarrhythmic drugs.

    Main Results:

    • Identification of individuals at risk for dysrhythmia has improved.
    • Enhanced methods for detection and monitoring are now available.
    • A range of potent new antiarrhythmic drugs have been developed.

    Conclusions:

    • The field of ventricular arrhythmias and sudden cardiac death is expanding.
    • Improved risk identification and therapeutic options necessitate broader understanding.
    • Family physicians and generalists require updated knowledge for patient management.